Issue 14 - October 2012
1) Competition Spotlight
Chief Scientific Officer of NextGen Metabolomics and President of Metabolic Analyses, Inc.
After completing his Ph.D. in Pharmaceutical Sciences/Natural Products Chemistry (University of Connecticut), Dr. Beecher began his research into the high-throughput chemical characterization of complex mixtures at the University of Illinois where he held the position of Associate Professor. He was editor of the NAPRALERT database from 1990 to 1998, Editor-in-Chief of the International Journal of Pharmacognosy, and served as a founding member of the Functional Foods Program of the University of Illinois. Dr. Beecher’s research continued at Bristol-Myers Squibb and Ancile Pharmaceuticals, where his focus shifted from secondary metabolism to primary metabolism with the establishment of the first Metabolomics platform in America at Paradigm Genetics from 2000 to 2002. In 2003, he founded two metabolomics-based companies: Metabolon, Inc. (platform technologies on human healthcare) and Metabolic Analysis, Inc. (informatics issues associated with metabolomics). Dr. Beecher compiled the first human metabolome in 2002 at Metabolic Analysis, and has been working toward the integration of metabolomic, proteomic, transcriptomics and genomic data. In addition to his primary appointment at the University of Michigan, Dr. Beecher serves as an Adjunct Professor at George Mason University, and is an Affiliate of the National Institute of Statistical Sciences. He holds many patents and publications in the areas of Metabolomics and Natural Products chemistry. (Source: http://www.metabolicanalyses.com/)
3) Biomarker Beacon
4) Metabolomics Current Contents
|21 Sep 2012
With $6M Grant, UC San Diego Bioengineers Take On Key Role in New NIH Common Funds Metabolomics Program
With a $6 million grant over five years, bioengineers from the University of California, San Diego will play a central role in a new program from the National Institutes of Health (NIH) to accelerate "metabolomics", an emerging field of biomedical research that offers a path to a wealth of information about a person’s nutrition, infection, health, disease status and more. In addition to powerful tools for diagnosis and disease follow-up, metabolomics technologies will transform researchers’ ability to define the mechanisms underlying disease, such as diabetes and obesity, and to develop new strategies for treatment.
Metabolomics is the study of small molecules called metabolites, found within cells and biological systems. Metabolites are produced or consumed in the chemical reactions that take place in the body to sustain life. The sum of all metabolites at any given moment — the metabolome — is a form of chemical readout of the state of health of the cell or body. One of the expected outcomes of this project is the ability to "metabo-type" individuals in order to get a detailed picture of their current metabolite profile, and recognize problems such as insulin resistance at an early stage. The effects of interventions such as changes in diet and exercise as well as pharmaceuticals could then be seen in updated metabo-type readings.
Shankar Subramaniam, professor and chair of the Department of Bioengineering at the UC San Diego Jacobs School of Engineering leads the metabolomics effort at UC San Diego, which involves coordinating the research cores and running the metabolome project’s Data Repository and Coordination Center (DRCC).
"I’m very excited about the prospect of collaborating with researchers in the Jacobs School, the School of Medicine, the San Diego Supercomputer Center and others across the campus and the country," said Subramaniam. "This work will lead to a systems level understanding of human physiology at the molecular level," said Subramaniam, who is the Joan and Irwin Jacobs Professor of Bioengineering and Systems Biology at UC San Diego. Subramaniam is also an Associate Director of the UC San Diego Institute of Engineering in Medicine.
The metabolomics project will provide insights into the millions of microorganisms living within us. The human body contains many more bacterial cells than human cells, and this metabolome project will provide new opportunities for researchers to understand the role that microorganisms living within the body play in human health, Subramaniam explained.
Through the data repository, the bioengineers and other researchers at UC San Diego will organize and present all data from the three metabolome core centers across the country, as well as other metabolomics efforts. The DRCC functions as a coordinating hub so that the awardees can function as a consortium. Subramaniam has extensive experience in integration of "omics" data and has experience coordinating other large scale projects. The data repository will be housed at the San Diego Supercomputer Center at UC San Diego, directed by Michael Norman.
This metabolomics project at UC San Diego is an extension of the successful Lipid Maps project. Lipids are just one metabolite, and the metabolomics work will extend researchers view beyond this metabolite to others, such as sugars, nucleic acids, amino acids and hormones.
Funding to UC San Diego for this project is $6 million over five years, part of a total investment by the NIH of $51.4 for the metabolomics project. The awards are supported by the NIH Common Fund.
|19 Sep 2012
NIH announces new program in metabolomics
Awards given to support research centers in an emerging field of research
The National Institutes of Health will invest $14.3 million this year, potentially investing more than $51.4 million over five years, to accelerate an emerging field of biomedical research known as metabolomics. Metabolomics is the study of small molecules called metabolites, found within cells and biological systems. Metabolites are produced or consumed in the chemical reactions that take place in the body to sustain life. The awards are supported by the NIH Common Fund.
The sum of all metabolites at any given moment — the metabolome — is a form of chemical readout of the state of health of the cell or body, and provides a wealth of information about nutrition, infection, health, and disease status. Metabolomics technologies have the potential to measure hundreds to thousands of unique metabolites, which can change as the result of disease, environmental exposures, or nutrition. In a clinical setting, metabolomics technologies can be powerful tools for diagnosis and disease follow-up. In basic research, these technologies will transform the ability of investigators to define the mechanisms underlying disease and to develop new strategies for treatment.
The NIH Common Fund is taking a comprehensive approach to increasing the research capacity in metabolomics by funding a variety of initiatives in this area, including training, technology development, standards synthesis, and data sharing capability for this new field.
"We are excited about the potential advances in technology that will enable metabolomics analysis to be conducted in basic and clinical settings, resulting in the discovery of new diagnostic tools and yielding important clues about disease mechanisms. The new cross-cutting metabolomics initiatives will allow for better data sharing and coordination of metabolomics efforts both nationally and internationally," said James M. Anderson, M.D., Ph.D., director of the NIH Division of Program Coordination, Planning and Strategic Initiatives, which oversees trans-NIH program areas, including those supported through the NIH Common Fund.
Three Regional Comprehensive Metabolomics Resource Cores have been awarded from the first round of applications, with the potential to award 2-3 additional at a later date. NIH will invest over $7 million this year in the first three centers, with plans to invest over $28 million over five years. The Regional Comprehensive Metabolomics Resource Cores will increase the national capacity to provide metabolomics profiling and data analysis services to investigators.
The University of Michigan's resource core is a fully integrated program that will provide researchers nationwide with the expertise and infrastructure for metabolomics in addition to training opportunities. The principal investigator of the grant is Dr. Charles Burant who is experienced in metabolomics, diabetes, and obesity research. He is assisted by Dr. Stephen Brown as a program coordinator on day-to-day operations.
University of California, Davis's resource core will serve clinical and biomedical researchers across the West Coast, with access to cutting-edge tools, collaborations and interpretation of data. The leader of this effort is Dr. Oliver Fiehn, who is experienced in metabolomics technologies and databases. He is assisted by Dr. William Wikoff as program coordinator.
The third award goes to Research Triangle Institute in Research Triangle Park, N.C., which is positioned as a leader of regional metabolomics center and offers a comprehensive range of services and collaborative opportunities for metabolomics technologies. The principal investigator of the grant is Dr. Susan Sumner, who has extensive experience and expertise in metabolomics technologies. She is assisted by Dr. Jason Burgess as program coordinator.
In addition to these three comprehensive metabolomics cores awards, a data repository and Coordination Center (DRCC) is also being awarded to the University of California, San Diego. NIH will invest $2 million this year in DRCC and potentially invest $6 million over five years. The DRCC will provide necessary organization and present all data from the cores and other metabolomics efforts to the biomedical research community. The DRCC functions as a coordinating hub so that the awardees can function as a consortium. Dr. Shankar Subramaniam, who has extensive experience in integration of omics data and has experience coordinating other large scale projects, leads the effort at UCSD. All awardees operate as cooperative agreements with NIH and collectively function as a consortium and lead collaborative activities related to metabolomics.
Source: NIH News
|5 Sep 2012
Grant funds West Coast Metabolomics Center
With a $9.3 million startup grant from the National Institutes of Health, the University of California, Davis, has announced plans to open the West Coast Metabolomics Center, a high-tech consortium of research and service laboratories that will help scientists better understand and develop more effective treatments for complex diseases like diabetes, cancer and atherosclerosis.
The facility, which will be housed within the UC Davis Genome Center, will celebrate its grand opening Oct. 8 with a mini-symposium featuring UC Davis and regional scientists, and corporate supporters.
Metabolomics is a new field that looks at the biochemical changes taking place in living cells during metabolism. The West Coast Metabolomics Center at UC Davis will use more than 30 mass spectrometers — instruments for analyzing chemical structures — to target thousands of different molecules produced in cells, allowing researchers to look at changes taking place at specific times and under specific environmental conditions.
"The NIH recognizes metabolism as a very important part of human physiology and disease processes," said Oliver Fiehn, professor of molecular and cellular biology and director of the new center. "When you analyze metabolism, you can tell the state of the body at the onset and during the progression of diseases ranging from cardiovascular disease to cancer."
The new center brings together existing UC Davis service facilities in mass spectrometry, nuclear magnetic resonance and imaging, with research labs across the campus, Fiehn said.
It will help researchers throughout the western U.S. with small grants for annual pilot and feasibility studies, provide courses, statistics and bioinformatics services, and perform metabolomic analyses on a fee-for-service basis. The center is designed to be self-sustaining within five years.
One of researchers who plans to use the new center is UC Davis Professor Bruce German, who studies lipid metabolism, especially in milk production, in the Department of Food Science and Technology.
"This new center shows the effects of the university’s long-term investments into biochemistry and genomics," German said.
Source: UC Davis News and Information
|8 & 15 Oct 2012||
Reactome Webinar Series
The first session on 8th October will describe Using Reactome Pathway Database. On 15th October, the second session will introduce the Reactome Functional Interaction Network Cytoscape plugin. If you are interesting in participating, please register at Eventbrite.
Feel free to pass this invitation along to colleagues who may benefit from learning about Reactome.
Registrants will receive detailed instructions about accessing the webinar via e-mail the Friday prior to the event. (Anyone registering between Friday and the close of registration will receive the message shortly after the registration is received, within normal business hours.)
Reactome is a collaboration between groups at the Ontario Institute for Cancer Research, Cold Spring Harbor Laboratory, New York University Medical Center, and The European Bioinformatics Institute. Freely available to everyone worldwide, the Reactome database offers pathway data encapsulating areas of human biology ranging from metabolism to complex events such as EGFR signaling, apoptosis and disease, extracted from the published literature by Reactome curatorial staff and cross-referenced to a wide range of standard biological databases. Reactome data and software are distributed under the terms of the Creative Commons Attribution 3.0 Unported License.
For more information contact:
Email: robin.haw [at] oicr.on.ca
|16-17 Oct 2012||
Metabolic Profiling & Lipidomics
This conference aims to discuss the latest developments in the rapidly evolving area of metabolic profiling with particular emphasis on the break out field of Lipidomics. Recent HPLC-MS advances now allow for individual molecular species of lipids to be isolated and identified. This meeting will detail the cutting edge research taking place as a result of these developments with emphasis on understanding not only lipid metabolism but also ascertaining the role of lipids in conditions such as atherosclerosis, inflammatory disease, arthritis, cancer, diabetes and Alzheimer's disease, with a view to improving treatment. As a whole focus will be drawn to the key technological developments being made in both the separation and detection analytical fields used in profiling as well as the area’s other key applications including toxicity assessment, functional genomics and nutrigenomics.
Other conference tracks at this event include Cancer Proteomics, Exosomes/Markers in Biological Fluids, and Informatics. Registered delegates will have access to all four meetings ensuring a very cost-effective trip.
In addition the event will also host two cutting edge business courses which can be viewed here.
For further information, please visit http://selectbiosciences.com/conferences/index.aspx?conf=MPL2012
|7-9 Nov 2012||
29th LC/MS Montreux Symposium
The Montreux LC/MS 2012 conference: Special highlights on Metabolomics and Clinical Chemistry
The field of LC/MS is continuously growing as is reflected by the participation of over 30 nationalities and by scientific contributions from a variety of research and development domains such as pharmaceutical, biotechnological, food, environmental and research on novel instrumentation and new LC/MS fields such as nanotechnology and microfluidics, UPLC, low flow rate spray techniques, proteomics, and systems biology.
In collaboration with the Metabolomics Society, a special joint parallel program for this rapidly emerging field is organized addressing the technology as well as novel systems-based biology approaches in pharma, nutrition, clinical chemistry, plant sciences, and medical biology. A parallel program is organized together with various Clinical Chemistry societies focusing on current and future LC/MS options in clinical diagnosis. Accreditation by related societies for the program as well as the short course has been applied for.
|9-11 Nov 2012||
Workshop on Holistic Analytical Technologies
for BioMedical, Food and Plant Sciences
Keynote speakers will comprise renowned scientists from academia and industry who will describe the remarkable advancement of analytical technologies (LC-MS, GC-MS, NMR) and data mining tools used for metabolomics research.
Preliminary list of Keynote speakers:
Dr. Toby J. Athersuch (Imperial College London)
Prof. Soren B Engelsen (University of Copenhagen)
Prof. Elaine Holmes (Imperial College London)
Prof. Ian Wilson (AstraZeneca UK)
Prof. Robert Verpoorte (Leiden University)
Dr. John Shockor (Waters)
Prof. Hermann Stuppner (University of Innsbruck)
Dr. Maria Klapa (FORTH)
Dr. Liz Want (Imperial College London)
Prof. Jean-Luc Wolfender (University of Geneva)
A poster session will provide the means for on-site open discussion to exchange ideas, and experiences. The workshop should provide an excellent learning opportunity, as well as a venue for the exchange of ideas among a highly interdisciplinary group of scientists. A special issue of Journal of Chromatography B will cover the works of the meeting.
For more information, visit the workshop website.
|27 Jan-1 Feb 2013||
Gordon Research Conference on Plant Lipids:
Structure, Metabolism & Function
Applications for this meeting must be submitted by December 30, 2012. Please apply early, as some meetings become oversubscribed (full) before this deadline. If the meeting is oversubscribed, it will be stated here. Note: Applications for oversubscribed meetings will only be considered by the Conference Chair if more seats become available due to cancellations.
Related Meeting Information
The Plant Lipids: Structure, Metabolism & Function Gordon Research Conference will be held in conjunction with the Plant Lipids: Structure, Metabolism & Function Gordon Research Seminar. Those interested in attending both meetings must submit an application for the GRS in addition to an application for the GRC. Please refer to the Plant Lipids: Structure, Metabolism & Function GRS web page for more information.
For more information, visit http://www.grc.org/programs.aspx?year=2013&program=plantlipid.
|8-10 Apr 2013||
2nd International Conference and Exhibition
on Metabolomics & Systems Biology
Metabolomics-2013 is a remarkable event which brings together a unique and International mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions making the conference a perfect platform to share experience, foster collaborations across industry and academia, and evaluate emerging technologies across the globe.
2nd International Conference and Exhibition on Metabolomics & Systems Biology will serve as a catalyst for the advances in the study of Metabolomics & Systems Biology by connecting scientists within and across disciplines at sessions and exhibition held at the venue, creates an environment conducive to information exchange, generation of new ideas, and acceleration of applications that benefit research in Metabolomics & Systems Biology.
For more information, visit http://omicsgroup.com/conferences/metabolomics-systems-biology-2013/.
7) Metabolomics Jobs
|Job Title||Employer||Location||Date Posted||Source|
||Hudson Shribman Scientific Recruitment||Cambridgeshire, UK (London, United Kingdom)||2-Oct-2012||LinkedIn.com
Professor of Biology
||University of Virginia
||Charlottesville, VA, USA
- Nutritional Metabolomics
||AgResearch Grasslands||Palmerston North, New Zealand||24-Sep-2012||SEEK
Professor – Professor (Director of Metabolomics)
||Beaumont Health System and the Beaumont Research Institute||Royal Oak, MI, USA||21-Sep-2012||Beaumont
Research Project in Bioanalysis/ Metabolomics
||Metabolomic Discoveries GmbH||Potsdam, Germany||20-Sep-2012||BioTOP
|Biochemistry and Molecular Biology Faculty Position||University of California, Los Angeles (UCLA)||Los Angeles, CA, USA
|Clinical Laboratory Director||Metabolon||Durham, NC, USA||15-Aug-2012||Metabolomics
||Stemina Biomarker Discovery
||Madison, WI, USA
Ian J. Forsythe, M.Sc.MetaboNews
University of Alberta
221 Athabasca Hall
Edmonton, AB, T6G 2E8, Canada
A single source destination for fee-for-service metabolic profiling including comprehensive metabolite identification, quantification, and analysis